Abstract: A dual wearable smart device system and a method of using the dual wearable smart device system for authenticating an electronic financial transaction are described. In one embodiment, a method for approving an electronic financial transaction using at least two wearable smart devices includes providing a first wearable smart device that is designated as a payment device for conducting electronic financial transactions. The method also includes providing a second wearable smart device that is designated as a confirmation device for confirming the electronic financial transactions by the first wearable smart device. The method includes initiating, by the first wearable smart device, an electronic financial transaction, and, approving, by the second wearable smart device, the electronic financial transaction initiated by the first wearable smart device. The method further includes authenticating the first wearable smart device to complete the electronic financial transaction.

Abstract: An apparatus for validating magnets on site, including a standard reference magnet for providing a governing reference, a reference magnet for providing a reference based on the governing reference, a gauss meter, a hall probe, and a scanner. The reference magnet is arranged to be taken on site for further magnetic validation and includes guide members to target a nominated magnetic field density.

Abstract: An apparatus for validating magnets on site, including a standard reference magnet for providing a governing reference, a reference magnet for providing a reference based on the governing reference, a gauss meter, a hall probe, and a scanner. The reference magnet is arranged to be taken on site for further magnetic validation and includes guide members to target a nominated magnetic field density.

Abstract: An apparatus for entrapping magnetic material comprising a magnetic sub-assembly and a retention trap removably attached thereto. The retention trap having an entrapment surface such that magnetic material drawn into the trap as a result of the magnetic influence of the magnetic sub-assembly, is magnetically held and mechanically trapped within said entrapment surface.

Abstract: A pipeline magnetic separator (10) having a magnet 20 including a length (24) that is to extend transverse of the separator chamber (19) to collect metal from flow passing in the direction (13) through the separator (10). The end surface (26) of the magnet (20) is hemispherical and is transverse of a longitudinal axis (33) of the magnet (20). Upstream of the magnet (20) is a flow diverter (25, 29).

Abstract: A pipeline magnetic separator (10) having a magnet 20 including a length (24) that is to extend transverse of the separator chamber (19) to collect metal from flow passing in the direction (13) through the separator (10). The end surface (26) of the magnet (20) is hemispherical and is transverse of a longitudinal axis (33) of the magnet (20). Upstream of the magnet (20) is a flow diverter (25, 29).

Abstract: An apparatus for entrapping magnetic material comprising a magnetic sub-assembly and a retention trap removably attached thereto. The retention trap having an entrapment surface such that magnetic material drawn into the trap as a result of the magnetic influence of the magnetic sub-assembly, is magnetically held and mechanically trapped within said entrapment surface.

Abstract: A magnetic screen assembly (13). The assembly (13) is to be located in a duct (10) to screen a flowable substance passing in a direction (11). The assembly (13) has a screening position (A) so that the substance passes through the screen, and a cleaning position (B) at which the screen assembly (13) is spaced outwardly relative to the housing (12) to facilitate cleaning of the assembly (13).

Abstract: Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers, wherein R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; Y is a bond, —C(?O), —S(?O)2—, —C(?O)O—, —C(O)NR3—, —C(?S)—NR3, —C(?NH)NR3 or —S(?O)2NR3— wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L1 is a divalent radical of formula -(Alk1)m(Q)n(Alk2)p- wherein m, n and p are independently 0 or 1, Q is (i) an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5-13 ring members, or (ii), in the case where both m and p are 0, a divalent radical of formula —X2-Q1- or -Q1-X2— wherein X2 is —O—, S— or NRA— wherein RA is hydrogen or optionally substituted C1-C3 alkyl, and Q1 is an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic r

Abstract: A suspension magnet assembly (10) having a magnet (24) with an arcuate lower surface, and a collector (27) movable from adjacent the magnet (24) to a position spaced from the magnet (24) to provide for the removal of collected material (14) from the assembly (10).

Abstract: Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers, wherein R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; Y is a bond, —C(?O), —S(?O)2—, —C(?O)O—, —C(O)NR3—, —C(?S)—NR3, —C(?NH)NR3 or —S(?O)2NR3— wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L1 is a divalent radical of formula -(Alk1)m(Q)n(Alk2)p- wherein m, n and p are independently 0 or 1, Q is (i) an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5-13 ring members, or (ii), in the case where both m and p are 0, a divalent radical of formula —X2-Q1- or -Q1-X2— wherein X2 is —O—, S— or NRA— wherein RA is hydrogen or optionally substituted C1-C3 alkyl, and Q1 is an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic r

Abstract: A suspension magnet assembly (10) having a magnet (24) with an arcuate lower surface, and a collector (27) movable from adjacent the magnet (24) to a position spaced from the magnet (24) to provide for the removal of collected material (14) from the assembly (10).

Abstract: Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers:

Abstract: A magnetic screen assembly (13). The assembly (13) is to be located in a duct (10) to screen a flowable substance passing in a direction (11). The assembly (13) has a screening position (A) so that the substance passes through the screen, and a cleaning position (B) at which the screen assembly (13) is spaced outwardly relative to the housing (12) to facilitate cleaning of the assembly (13).

Abstract: Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers:

Abstract: A magnetic separation apparatus (10) for separating magnetic materials from non-magnetic materials in a material flow comprising self cleaning magnetic separators (15) comprising: a cylinder (20) having a first end closer to a material flow than its second end in use, a piston (25) slidingly mounted within the cylinder (20), and a magnetic shaft (30) extending from the piston (25), the piston (25) and cylinder (20) adapted to move the magnetic shaft (30) between an extended position (31) and a retracted position (32), such that in the extended position (32), at least a sleeveless portion of an outer surface of the magnetic shaft (30) is exposed to the material flow and in the retracted position the magnetic portion is retracted substantially or wholly within the cylinder (20), the apparatus including a protected shaft wiper (120) and shaft seal (125) within the first end of the cylinder (20) for removing extracted magnetics.

Abstract: A magnetic separation apparatus (10) for separating magnetic materials from non-magnetic materials in a material flow comprising self cleaning magnetic separators (15) comprising: a cylinder (20) having a first end closer to a material flow than its second end in use, a piston (25) slidingly mounted within the cylinder (20), and a magnetic shaft (30) extending from the piston (25), the piston (25) and cylinder (20) adapted to move the magnetic shaft (30) between an extended position (31) and a retracted position (32), such that in the extended position (32), at least a sleeveless portion of an outer surface of the magnetic shaft (30) is exposed to the material flow and in the retracted position the magnetic portion is retracted substantially or wholly within the cylinder (20), the apparatus including a protected shaft wiper (120) and shaft seal (125) within the first end of the cylinder (20) for removing extracted magnetics.

Abstract: Compounds of formula (I) are PLK inhibitors, useful for the treatment of cell proliferative diseases: wherein R1 is hydrogen, or an optionally substituted (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl or (C3-C6)cycloalkyl group; R2 is hydrogen, or an optionally substituted (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl or (C3-C6)cycloalkyl group; R3 is hydrogen, —CN, hydroxyl, halogen, optionally substituted (C1C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl or (C3-C6)cycloalkyl, —NR5R6 or C1-C4 alkoxy, wherein R5 and R6 are independently hydrogen or optionally substituted (C1-C6)alkyl; ring A is an optionally substituted mono- or bi-cyclic carbocyclic or heterocyclic ring or a ring system having up to 12 ring atoms; T is a radical of formula R-L1-Y1— wherein L1 and Y1 are as defined in the claims and R is an carbon-linked, alpha alpha disubstituted amino acid or amino acid ester residue.

Abstract: Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers.

Abstract: Compound of formula (I) are inhibitors of Polo-like kinases (PLKs), and are useful in treatment of cell proliferative diseases: wherein R1 and R2 are hydrogen, or an optionally substituted (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl or (C3-C6)cycloalkyl group; R3 and R3? are independently selected from hydrogen, —CN, hydroxyl, halogen, optionally substituted (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl or (C3-C6)cycloalkyl, —NR5R6 or C1-C4 alkoxy, wherein R5 and R6 are independently hydrogen or optionally substituted (C1-C6)alkyl; ring A is an optionally substituted mono- or bi-cyclic carbocyclic or heterocyclic ring or a ring system having up to 12 ring atoms; T is a radical of formula R-L1-Y1— wherein R is an alpha amino acid or alpha amino acid ester motif, linked to ring A by linker R-L1-Y1— as defined in the claims.